Dallas Wings Get Bad News on Monday
The Dallas Wings will take the court without their rookie point guard Paige Bueckers on Tuesday night against the Seattle Storm after she was ruled out under the WNBA's concussion protocol on Monday.
Advertisement
Bueckers, the No. 1 overall pick in the 2025 WNBA Draft, sustained the injury late in Thursday's 97-92 loss to the Chicago Sky, and Dallas-based reporter Grant Afseth announced on X that she would miss at least Tuesday's game.
This latest setback comes as the Wings continue to search for their identity early in the season, sitting at 1-6 after back-to-back losses to Chicago, tied for last place in the league standings.
Despite the lofty expectations surrounding Bueckers entering her rookie campaign, the Wings have struggled to gain traction.
In 2024, Dallas finished with a 9-31 record, ranking fifth in the WNBA's Western Conference under head coach Latricia Trammell.
Advertisement
Entering 2025, Dallas hoped to improve upon that record by blending veteran scorers like Arike Ogunbowale (22.2 points per game last season) and emerging talent in NaLyssa Smith, Maddy Siegrist, DiJonai Carrington and Bueckers.
However, the season has not gone as planned.
Dallas Wings guards Paige Bueckers (5) and DiJonai Carrington (21).David Butler II-Imagn Images
After opening the year with four straight defeats, the Wings finally notched a win against the Connecticut Sun on May 27 with a 109-87 victory featuring 21 points, seven assists and five rebounds from Bueckers.
Unfortunately, they followed that up with consecutive losses to the Sky.
Through her first six games, Bueckers was averaging 14.7 points, 6.7 assists and 4.7 rebounds per contest, while leading the team in assists, steals (2.0) and blocks (1.0).
Advertisement
Related: Lexie Hull's Mother Sends Indiana Fever Message After Third Straight Loss
Related: Angel Reese Sends Message After Announcement on Friday
This story was originally reported by Athlon Sports on Jun 3, 2025, where it first appeared.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
an hour ago
- CNN
CNN contributor sounds off on the big issue of sex toys thrown at WNBA games
CNN contributor sounds off on the big issue of sex toys thrown at WNBA games CNN Contributor Cari Champion says that WNBA players deserve respect in the wake of sex toys being thrown on the court during games. 01:21 - Source: CNN Automated CNN Shorts 11 videos CNN contributor sounds off on the big issue of sex toys thrown at WNBA games CNN Contributor Cari Champion says that WNBA players deserve respect in the wake of sex toys being thrown on the court during games. 01:21 - Source: CNN Epstein survivor doubts he died by suicide CNN's Randi Kaye speaks with one woman about her experiences with Jeffrey Epstein when she was just 16, and why she thinks he didn't die by suicide. 01:32 - Source: CNN Epstein survivor speaks out on Maxwell CNN's Randi Kaye speaks with one woman about her experiences with Jeffrey Epstein when she was just 16. 01:13 - Source: CNN Cristiano Ronaldo and his partner Georgina Rodríguez are engaged 00:35 - Source: CNN Armored personnel carriers line up near Washington Monument Five armored personnel carriers parked overnight near the Washington Monument after President Donald Trump's decision yesterday to deploy the National Guard in the US capital. 00:51 - Source: CNN Torrential rains trigger flooding in Chattanooga Chattanooga, Tennessee recorded its second-wettest day on record, receiving more than 6 inches of rain and nearly twice the city's typical August rainfall in a single day. The deluge has triggered significant flooding and numerous water rescues. 01:09 - Source: CNN Anderson gives his take on Trump admin's call to vet Smithsonian museums CNN's Anderson Cooper explores what the Trump administration's declaration that it intends to take control over the Smithsonian museums says about how President Trump views history. 04:15 - Source: CNN 'Deeply dangerous': Wes Moore reacts to National Guard deployed in DC Maryland Democratic Governor Wes Moore spoke with CNN's Anderson Cooper about the potential deployment of federal troops in Baltimore after President Donald Trump said he is placing Washington, DC's, police department 'under direct federal control' and deploying National Guard troops to the nation's capital. 01:57 - Source: CNN A glacier outburst is underway in Alaska A wave of water gushing out of an Alaskan glacier is threatening significant, potentially record-breaking flooding in Juneau for the third consecutive August. 00:44 - Source: CNN Mayors across US react to Trump's warnings of federal intervention Democratic mayors across the US react to President Donald Trump placing DC police 'under direct federal control' and deploying the National Guard to crack down on crime. 01:10 - Source: CNN
New York Times
2 hours ago
- New York Times
How Netflix could've had a fairy-tale ending to its Cowboys documentary
Everything lined up perfectly for a fairy-tale ending. The crew was all there, ready to film Jerry Jones as the Dallas Cowboys finally made their first deep playoff run since the glory years of the 1990s. Instead, the cameras captured Jones in his AT&T Stadium owner's suite as he watched every minute of what was arguably the worst loss in franchise history. That didn't stop production. Netflix continued on and the final product will be available on the subscription-based streaming service Aug. 19. It's called, 'America's Team: The Gambler and His Cowboys.' Advertisement Jones could've waited a few days to have the official premiere for the series at a theater in Dallas. The team, currently in Oxnard, Calif., for training camp, returns to Texas on Thursday. But the Hollywood premiere was too good to pass up. Jones and his family were in attendance at The Egyptian Theatre on Monday night for a debut of one of the episodes. 'I'm often asked the question,' Jones says in the eight-part series, 'why don't I hire a general manager. I've had people that say, 'Jerry, you subject yourself to so much criticism. You need a buffer.' 'I don't like it like that. I like the pain.' Jerry Jones at the Hollywood premiere for his Netflix series 'America's Team' when asked about the lack of postseason success since the 1990s — Jon Machota (@jonmachota) August 12, 2025 The pain is all over his face as the Cowboys, who were on a league-best 16-game home winning streak, turned in an embarrassing performance against the visiting Green Bay Packers in the 2023 wild-card round. Dallas trailed 27-0 late in the second quarter and were down 48-16 midway through the fourth before ultimately losing 48-32. 'Kiss my ass,' Jones says at one point during the game. He drops a simple F-bomb a little later. And then the perfect summary: 'Boy, what a disaster.' 'This loss hurt us in every way more than any one we've ever had,' Jones says. The cameras even rolled as Jones consoled players in the postgame locker room. 'It's a disappointment,' Jones told Micah Parsons, 'but it wasn't because of you.' The cameras were following Jones because the footage was supposed to go perfectly with the series that recaps Dallas' dominance early in Jones' time owning the franchise. They were around because this was finally the season when Jones put Jimmy Johnson in the Ring of Honor. In the end, the final product is a look back on the glory years that many Cowboys fans have grown tired of hearing about. A 29-year Super Bowl drought has a way of doing that, especially when the focal point of the documentary is the person most responsible for that drought. Emmitt Smith when asked about Jerry Jones' role in the Cowboys' Super Bowl drought — Jon Machota (@jonmachota) August 12, 2025 The gold standard for these types of documentaries is 'The Last Dance.' The subject is Michael Jordan and the 1990s Chicago Bulls, who won six championships in an eight-year span. The difference in the two series is that Jordan rarely does interviews. It was fascinating to hear so much information that had never been revealed. Advertisement Jones talks all the time. Several of the other key subjects in 'America's Team' are Michael Irvin, Deion Sanders, Troy Aikman, Emmitt Smith, Jimmy Johnson and Barry Switzer. Most Cowboys fans have heard from all of them on the topics discussed because they are all media-friendly and several have prominent TV jobs. But it's understandable why Netflix would be interested in the most valuable sports franchise that turns in outstanding TV numbers even with its lack of playoff success over the past three decades. The production of the series should be applauded. Cameras are with Jones as he's with his family for their traditional Thanksgiving gathering in Missouri. They have footage of Jones hunting, flying in his helicopter and visiting his father's grave. Similar to 'The Last Dance', there are issues within the team that led to a breakup when the franchise is in the midst of winning championships. How many more rings could Jordan have won if Jerry Krause tried to keep the group together? How many more rings could Emmitt, Michael and Troy have won if Jones and Johnson could have put their egos aside? The two still can't agree on who deserves the credit for the Herschel Walker trade. 'It wasn't just Jerry,' Johnson says in the documentary. 'We both screwed it up.' Jones is arguably the greatest businessman to ever be involved in sports. But every year that passes without a return to at least the NFC Championship Game, the more it becomes clear that Johnson deserves the larger part of the credit for the dynasty run. Cowboys owner Jerry Jones at The Egyptian Theatre Hollywood for the premiere of the Netflix series 'America's Team': 'We have a very big following, both the ones that want to see us get our ass kicked and the ones that want to see us win.' — Jon Machota (@jonmachota) August 12, 2025 'You know, now that I think about it, I don't know what this has proven,' Jones says in the documentary. 'As a matter of fact, when I start trying to add up the pluses and the takeaways and what have you, maybe all it has exposed is a flawed Jerry. 'But what I can say, with absolute certainty, this has been one hell of a f—— ride.' Advertisement The storybook ending almost never happens in real life. Jordan could have stayed retired with the final image of his career being the game-winning shot in Utah. But even he had to come back and play for the Washington Wizards. Putting Johnson in the Ring of Honor during the same season when Dallas finally adds a sixth Lombardi Trophy sounds like pure fiction. And it was. But production continued. Were they supposed to hold all of their footage until the Cowboys finally get back on top? 'They're not chasing the Philadelphia Eagles or whoever is the best team in the (NFC) East,' Sanders said in the documentary. 'That's not what they're chasing right now. They're chasing the former Cowboys. That's who they're chasing. And that's a beautiful thing.' Spot the pattern. Connect the terms Find the hidden link between sports terms Play today's puzzle
Yahoo
3 hours ago
- Yahoo
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (''2510') anticipated before the end of 2025 Updated '2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ('Instil') (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2025 financial results and provided a corporate update. Recent Highlights: In June, announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer In July, announced the Investigational New Drug (IND) application for '2510 was cleared by the U.S. FDA In July, ImmuneOnco, Instil's collaborator, announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of '2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China by ImmuneOnco In August, ImmuneOnco announced that an abstract has been accepted for poster presentation at IASLC's 2025 World Conference on Lung Cancer (September 6th-9th, 2025), which will provide updated results from additional patients with relapsed/refractory squamous-NSCLC treated with '2510 as monotherapy Second Quarter 2025 Financial and Operating Results: As of June 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $103.6 million, which consisted of $7.7 million in cash and cash equivalents, approximately $0.2 million in restricted cash, $84.1 million in marketable securities, and $11.7 million in long-term investments, compared to $115.1 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2024, consisting of $8.8 million in cash and cash equivalents, $1.8 million in restricted cash, and $104.5 million in marketable securities. Instil expects that its cash, cash equivalents, marketable securities and long-term investments as of June 30, 2025 will enable it to fund its operating plan beyond 2026. In-process research and development expenses were $10.0 million for both the three and six months ended June 30, 2025, compared to nil for both the three and six months ended June 30, 2024. Research and development expenses were $6.7 million and $12.1 million for the three and six months ended June 30, 2025, respectively, compared to $2.9 million and $10.2 million for the three and six months ended June 30, 2024, respectively. General and administrative expenses were $6.2 million and $15.3 million for the three and six months ended June 30, 2025, respectively, compared to $10.7 million and $23.1 million for the three and six months ended June 30, 2024, respectively. Restructuring and impairment charges were $0.5 million and $16.6 million for the three and six months ended June 30, 2025, respectively, compared to $0.5 million and $4.8 million for three and six months ended June 30, 2024, respectively. Net loss per share, basic and diluted were $3.24 and $7.55 for the three and six months ended June 30, 2025, respectively, compared to $2.29 and $6.03 for the three and six months ended June 30, 2024, respectively. Non-GAAP net loss per share, basic and diluted, were $2.88 and $4.21 for the three and six months ended June 30, 2025, respectively, compared to $1.57 and $3.95 for the three and six months ended June 30, 2024, respectively. Note Regarding Use of Non-GAAP Financial Measures In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles ('GAAP'). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil's operating results. In addition, these non-GAAP financial measures are among the indicators Instil's management uses for planning purposes and to measure Instil's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. About Instil Bio Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'exploring,' 'future,' 'intends,' 'may,' 'plans,' 'potential,' 'projects,' 'targets' and 'will' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements regarding our expectations with respect to the therapeutic potential of AXN-2510/IMM2510, clinical development of AXN-2510/IMM2510, including the initiation of clinical trials for AXN-2510/IMM2510 and the generation and presentation of clinical data for AXN-2510/IMM2510 and the timing thereof; research, development, regulatory and clinical plans for AXN-2510/IMM2510; Instil's expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties associated with the costly and time-consuming drug product development process and the uncertainty of clinical success; the risks inherent in relying on collaborators and other third parties, including for manufacturing and generating clinical data, and the ability to rely on any such data from clinical trials in China in regulatory filings submitted to regulatory authorities outside of China; the risks and uncertainties related to successfully making regulatory submissions and initiating, enrolling, completing and reporting data from clinical trials, particularly collaborator-led clinical trials, as well as the risks that results obtained in any clinical trials to date may not be indicative of results obtained in ongoing or future trials and that product candidates may otherwise not be effective treatments in their planned indications; risks related to macroeconomic conditions, including as a result of international conflicts and U.S.-China trade and political tensions, as well as interest rates, inflation, tariffs and other factors, which could materially and adversely affect our business and operations and those of our collaborators; the risks and uncertainties associated with the time-consuming and uncertain regulatory approval process and the sufficiency of Instil's cash resources; and other risks and uncertainties affecting Instil's plans and development programs, including those discussed in the section titled 'Risk Factors' in Instil's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the SEC, as well as Instil's other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law. Contacts: Investor Relations:1-972-499-3350 investorrelations@ INSTIL BIO, FINANCIAL DATA (Unaudited; in thousands, except share and per share amounts) Selected Condensed Consolidated Balance Sheet Data June 30, 2025 December 31, 2024 Cash, cash equivalents, restricted cash, marketablesecurities and long-term investments $ 103,632 $ 115,145 Total assets $ 230,986 $ 263,567 Total liabilities $ 99,316 $ 94,131 Total stockholders' equity $ 131,670 $ 169,436 Condensed Consolidated Statements of Operations Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Operating expenses: In-process research and development $ 10,000 $ — $ 10,000 $ — Research and development 6,743 2,921 12,114 10,177 General and administrative 6,157 10,706 15,266 23,130 Restructuring and impairment charges 540 508 16,622 4,783 Total operating expenses 23,440 14,135 54,002 38,090 Loss from operations (23,440 ) (14,135 ) (54,002 ) (38,090 ) Interest income 1,044 1,919 2,219 3,981 Interest expense (1,582 ) (1,999 ) (2,680 ) (3,980 ) Other rental income 2,242 — 4,484 — Other income (expense), net 342 (702 ) 385 (1,130 ) Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Weighted-average shares used incomputing net loss per share, basic anddiluted 6,596,975 6,503,913 6,564,994 6,503,913 INSTIL BIO, of GAAP to Non-GAAP Net Loss and Net Loss per Share (Unaudited; in thousands, except share and per share amounts) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Adjustments: Non-cash stock-based compensationexpense 1,824 4,173 5,319 8,688 Restructuring and impairmentcharges 540 508 16,622 4,783 Non-GAAP net loss $ (19,030 ) $ (10,236 ) $ (27,653 ) $ (25,748 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Adjustments: Non-cash stock-based compensationexpense per share 0.28 0.64 0.81 1.34 Restructuring and impairmentcharges per share 0.08 0.08 2.53 0.74 Non-GAAP net loss per share, basicand diluted* $ (2.88 ) $ (1.57 ) $ (4.21 ) $ (3.95 ) Weighted-average shares outstanding,basic and diluted 6,596,975 6,503,913 6,564,994 6,503,913 * Non-GAAP net loss per share, basic and diluted may not total due to in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
